Results 51 to 60 of about 1,426 (171)

A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patientsResearch in context

The Lancet Regional Health. Western Pacific
Summary: Background: Teprotumumab significantly improved proptosis and diplopia in patients with active, moderate-to-severe thyroid eye disease (TED) in previous North American and European studies. This is the first evaluation of efficacy and safety of
Yuji Hiromatsu, Eri Ishikawa, Ai Kozaki, Yasuhiro Takahashi, Mika Tanabe, Ken Hayashi, Yukihiro Imagawa, Kazutoyo Kaneda, Masashi Mimura, Xiaoxian Dai, Tomoko Hayashida, Takashi Akamizu   +11 more
doaj   +1 more source

Assessment of Ocular Misalignment Before and After Teprotumumab Therapy in Patients With Thyroid Orbitopathy

, 2022
Diplopia due to thyroid orbitopathy can be disabling with limited management options that include prisms or strabismus surgery. Teprotumumab, an insulin like growth factor one (IGF-1) antagonist, reduces proptosis and improves double vision. Two clinical
Alexander M. Solomon; Gibran Merchant; Madhura Tamhankar
core  

Novel teprotumumab treatment of severe thyroid dermopathy; ototoxicity as an adverse side effect [PDF]

, 2023
Pretibial myxedema, more generally thyroid dermopathy, results from mucopolysaccharide accumulation in the dermis, typically between the knee and dorsal foot.
Patel, Riya T, Ramey, Nicholas, Grider, Douglas J, Douglas J Grider, Patel, Riya T ; Grider, Douglas J ; Ramey, Nicholas, Riya T Patel, Nicholas Ramey   +6 more
core   +1 more source

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab

Clinical Case Reports, 2022
We report a 51‐year‐old woman with thyroid eye disease and biopsy‐proven pretibial myxedema that was subsequently treated with teprotumumab with improvement.
Brendan K. Bowens, Eva Chou, David P. LaChance, James R. Huynh, Patrick Voorhees, Thanh C. Do, Mohamed K. M. Shakir, Thanh D. Hoang   +7 more
doaj   +1 more source

Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database

Clinical Endocrinology, Volume 102, Issue 4, Page 482-489, April 2025.
ABSTRACT Objective To estimate the incidence, prevalence, patient characteristics and healthcare utilization patterns of moderate to severe thyroid eye disease (TED) in the United States. Design Retrospective review of medical and prescription claims data from the Inovalon deidentified claims database. Patients Patients with moderate to severe TED were
Marius N. Stan, Lilly H. Wagner, Kharisa N. Rachmasari, Brett Venker, Joel Arackal, Jingyu Wang, Lesley‐Ann Miller‐Wilson, Jennifer Schwinn, Paola Mina‐Osorio   +8 more
wiley   +1 more source

Real World Experience with Teprotumumab in Patients with Dysthyroid Optic Neuropathy (DON)

, 2023
Teprotumumab, an insulin-like growth factor I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life (QOL) in patients with active thyroid eye disease (TED) in clinical trials.1,2 The trials excluded ...
Madhura Tamhankar; Alvin Relucio
core  

The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review

The Laryngoscope, Volume 135, Issue 2, Page 491-506, February 2025.
This study assesses the current landscape of the literature regarding ototoxic effects relating to the usage of monoclonal antibodies. Where available, audiometric data are discussed and a proposed mechanism of action for otologic effect is provided. Objective To ascertain trends in ototoxicity observed with monoclonal antibodies (mABs) and understand ...
Priya Arya, Yansy Salmerón, Alexandra E. Quimby, Kevin Wong, Jason A. Brant, Tiffany P. Hwa   +5 more
wiley   +1 more source

Efficacy of teprotumumab N01 (IBI311), an IGF-1R inhibitor, for thyroid eye disease patients who had failed glucocorticoids [PDF]

International Journal of Ophthalmology
AIM: To explore the efficacy of teprotumumab N01 (IBI311), an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, in thyroid eye disease (TED) patients who had failed glucocorticoids.
Wei Zhao, Tian-Yuan Li, Ying Na, Xin-Yi Gou, Ling-Li Zhou, Yi-Hua Xu, Jin Cheng, Xiu-Ying Zhang, Li-Nong Ji   +8 more
doaj   +1 more source

Teprotumumab for Thyroid-Associated Ophthalmopathy [PDF]

, 2017
BACKGROUND: Thyroid-associated ophthalmopathy, a condition commonly associated with Graves' disease, remains inadequately treated. Current medical therapies, which primarily consist of glucocorticoids, have limited efficacy and present safety concerns.
Raymond S. Douglas, Rosa A. Tang, Tang, Rosa A, Gigantelli, James W, James C. Fleming, Woodward, Richard M, Shriver, Erin M, Dailey, Roger A, Brent R. Hayek, Richard M. Woodward, Couch, Steven M, Douglas, Raymond S., Mario Salvi, James W. Gigantelli, Gerald J. Harris, Robert A. Goldberg, Goldberg, Robert A, ANTONELLI, ALESSANDRO, Harris, Gerald J, George J. Kahaly, Salvi, Mario, Kahaly, George J, Fleming, James C, Erin M. Shriver, Hayek, Brent R, Guido Magni, Roger A. Dailey, Alessandro Antonelli, Daniel G. Ezra, Steven M. Couch, Smith, Terry J, Gabriel, Kathleen, Kathleen Gabriel, Magni, Guido, Hink, Eric M, Terry J. Smith, Eric M. Hink, Ezra, Daniel G   +37 more
core   +4 more sources

Long-Term Follow-Up of a Case of Severe Hyperglycemia Requiring Hospitalization after Third Dose of Teprotumumab: A Case Report

Case Reports in Ophthalmology
Introduction: In 2020, teprotumumab became the first FDA-approved treatment for thyroid eye disease (TED). In clinical trials, hyperglycemia had been described as mild and controlled with medication.
Preeya Mehta, Trevor Angell, Vivian LeTran, Michael Lin, Annie Nguyen, Sandy Zhang-Nunes   +5 more
doaj   +1 more source